This article is more than 5 years old. Information may no longer be current.

Alphaeon to market Amaris excimer laser system in US

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alphaeon announced that it acquired a U.S. license from Schwind eye-tech solutions to market the Amaris excimer laser system, according to a press release.

Alphaeon, a wholly owned subsidiary of Strathspey Crown Holdings, will oversee the U.S. Food and Drug Administration clinical trial required to market the product in the United States.

The amount of the license was not disclosed.

The Amaris system for laser vision correction procedures was launched in 2007 and has been used in more than 120 countries.

According to published data of more than 10,000 eyes, 97% of nearsighted patients treated with the Amaris achieved 20/20 or better distance vision 3 months after treatment, the release said.